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Introduction / objectives
O2 enriched pharmaceutical chlorite [NaClO2 German
Drug Codex monograph DAC N-055, 1990] contains
Na2Cl2O6 formerly called TCDO, (NaClO2)4·O2 fights
tissue infections and promotes wound granulation of
radiogenic ulcers [http://www-pub.iaea.org/mtcd/publi-
cations/pdf/te_1300_web.pdf]. Under our hygienic con-
ditions the intra- and postoperative topical use of
0.045% DAC N-055 helps us to deal with bone & tissue
infections in orthopaedic surgery in Mazar. Here we
document 4 cases out of the total number of 26
patients, we monitored in the former Military Hospital
in Mazar 2004 - 2006 to familiarize ourselves with this
German drug first registered as Oxoferin
® in 1983.
Methods
The speed of
·ClO2 release from 0.045 % DAC N-055
(max. 160 ppm) increases with decreasing pH.
·ClO2
induces no resistance. In all patients the field of surgical
intervention is rinsed several times with 0.045 % DAC
N-055 in saline especially during the operation, espe-
cially before wound closure and dressed with cotton
gauzes kept moist till the patient is discharged home.
Post-OP irrigations are practised with 0.045 % DAC N-
055 for septic arthritis (closed method) and osteomylitis
(open method).
Results
1/2 septic arthritis, osteomyelitis cases and 2/22 osteo-
myelitis cases are photo-documented. Without antibio-
tics, septic arthritis had an excellent functional outcome
after 6 weeks, the open fracture with skin defect
received mesh graft on excellent granulation after 1
month and was completely closed after 3 months. 11/22
osteomyelitis cases could be monitored for 6 to 18
months, 6 cases relapsed within this time, for 8/11
patients antibiotics were not available.
Conclusion
If 4.5% DAC N-055 could be sold in Afghanistan at 50%
of the price of the finished drug Oxoferin
® sold in Paki-
stan this could help poor patients in traumatology.
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